1. Scrip
  2. >>Business

Timeline At The Top: What Witty Did At GSK

 
• By Lucie Ellis-Taitt

Sir Andrew Witty has announced his intention to retire as CEO of GlaxoSmithKline PLC in March 2017. Having joined as a graduate trainee in 1985, he became CEO in 2008. Eight years is a long time to head up a big pharma company, and while Sir Andrew's detractors might argue that he has failed to deliver shareholder value, none can argue that it has been for lack of action. Here is a timeline of major events at GSK since the start of his tenure at the top.

Sir Andrew Witty has announced his intention to retire as CEO of GlaxoSmithKline PLC in March 2017. Having joined as a graduate trainee in 1985, he became CEO in 2008. Eight years is a long time to head up a big pharma company, and while Sir Andrew's detractors might argue that he has failed to deliver shareholder value, none can argue that it has been for lack of action. Here is a timeline of major events at GSK since the start of his tenure at the top.

Please note that this timeline may not display properly in all browsers. If you cannot see it, try using an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.